Biocon Limited, an innovation-led global biopharmaceutical company, announced the signing of a semi-exclusive partnership agreement with Zentiva, a leading pharmaceutical company in Europe, for the commercialization of Liraglutide, a drug-device combination suggested for the treatment and management of Type 2 diabetes and obesity.
Under the terms of this agreement, Biocon will be in charge of manufacturing and supplying Liraglutide to Zentiva for commercialization in 30 European countries. Biocon will also retain the right to commercialise this product in the region under its own brand.
Zentiva has a long history of producing branded generics in a variety of therapeutic areas, including diabetes, cardiology, respiratory, and oncology. Zentiva is rapidly expanding its reach in Europe and beyond, thanks to a commitment to R&D and four flagship manufacturing facilities in Bucharest, Prague, and Ankleshwar.
At around 9.17 AM, Biocon was trading at Rs281.35 up by 0.45% from its previous closing of Rs280.10 on the BSE.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.